Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-06-11 7:51 pm Purchase |
2025-06-04 | 13G | Mereo BioPharma Group plc MREO |
Northpond Ventures, LP | 54,521,000 6.900% |
54,521,000 (New Position) |
Filing History |
| 2025-05-15 10:46 am Sale |
2025-03-31 | 13G | Mereo BioPharma Group plc MREO |
Rock Springs Capital Management LP | 33,421,235 4.200% |
-14,249,615 (-29.89%) |
Filing History |
| 2025-05-14 4:34 pm Purchase |
2025-03-31 | 13G | Mereo BioPharma Group plc MREO |
JANUS HENDERSON GROUP PLC JHG |
22,735,121 14.300% |
6,817,862 (+42.83%) |
Filing History |
| 2025-05-12 09:01 am Purchase |
2025-03-31 | 13G | Mereo BioPharma Group plc MREO |
Adage Capital Management, L.P. | 8,503,780 1.070% |
8,503,780 (New Position) |
Filing History |
| 2025-04-04 12:39 pm Purchase |
2025-04-01 | 13G | Mereo BioPharma Group plc MREO |
Frazier Life Sciences Public Fund, L.P. | 40,349,315 5.100% |
40,349,315 (New Position) |
Filing History |
| 2025-02-12 09:34 am Sale |
2024-12-31 | 13G | Mereo BioPharma Group plc MREO |
ADAGE CAPITAL PARTNERS GP L.L.C. | 43,575,065 5.620% |
-6,674,935 (-13.28%) |
Filing History |
| 2024-12-06 11:37 am Purchase |
2024-11-29 | 13G | Mereo BioPharma Group plc MREO |
JANUS HENDERSON GROUP PLC JHG |
15,917,259 10.300% |
3,571,393 (+28.93%) |
Filing History |
| 2024-11-14 4:18 pm Sale |
2024-09-30 | 13G | Mereo BioPharma Group plc MREO |
SUVRETTA CAPITAL MANAGEMENT LLC | 0 0.000% |
-36,854,190 (Position Closed) |
Filing History |
| 2024-11-14 3:30 pm Sale |
2024-09-30 | 13G | Mereo BioPharma Group plc MREO |
Soleus Private Equity Fund III, L.P. | 4,234,765 0.500% |
-44,652,330 (-91.34%) |
Filing History |
| 2024-11-14 11:44 am Purchase |
2024-09-30 | 13G | Mereo BioPharma Group plc MREO |
JANUS HENDERSON GROUP PLC JHG |
12,345,866 8.000% |
4,400,162 (+55.38%) |
Filing History |
| 2024-11-12 4:49 pm Purchase |
2024-09-30 | 13G | Mereo BioPharma Group plc MREO |
Rock Springs Capital Management LP | 47,670,850 6.200% |
7,751,595 (+19.42%) |
Filing History |
| 2024-07-11 11:46 am Purchase |
2024-07-01 | 13G | Mereo BioPharma Group plc MREO |
JANUS HENDERSON GROUP PLC JHG |
7,945,704 5.200% |
7,945,704 (New Position) |
Filing History |
| 2024-06-17 4:32 pm Purchase |
2024-06-17 | 13D | Mereo BioPharma Group plc MREO |
Rubric Capital Management LP | 108,486,735 14.200% |
8,771,750 (+8.80%) |
Filing History |
| 2024-04-16 2:58 pm Purchase |
2024-04-15 | 13D | Mereo BioPharma Group plc MREO |
Rubric Capital Management LP | 99,714,985 14.220% |
10,100 (+0.01%) |
Filing History |
| 2024-02-14 6:51 pm Sale |
2023-12-31 | 13G | Mereo BioPharma Group plc MREO |
ORBIMED ADVISORS LLC | 0 0.000% |
-10,378,591 (Position Closed) |
Filing History |
| 2024-02-14 2:11 pm Unchanged |
2023-12-31 | 13G | Mereo BioPharma Group plc MREO |
Rock Springs Capital Management LP | 39,919,255 5.690% |
0 (Unchanged) |
Filing History |
| 2024-02-14 2:10 pm Purchase |
2023-07-03 | 13G | Mereo BioPharma Group plc MREO |
Rock Springs Capital Management LP | 39,919,255 6.380% |
8,694,770 (+27.85%) |
Filing History |
| 2024-02-14 12:36 pm Purchase |
2023-12-31 | 13G | Mereo BioPharma Group plc MREO |
MANGROVE PARTNERS IM LLC | 43,764,465 6.240% |
43,764,465 (New Position) |
Filing History |
| 2024-02-13 5:26 pm Purchase |
2023-12-31 | 13G | Mereo BioPharma Group plc MREO |
SUVRETTA CAPITAL MANAGEMENT LLC | 36,854,190 5.300% |
32,000 (+0.09%) |
Filing History |
| 2024-02-06 4:15 pm Purchase |
2023-12-31 | 13G | Mereo BioPharma Group plc MREO |
Soleus Private Equity Fund III, L.P. | 48,887,095 7.000% |
500,000 (+1.03%) |
Filing History |